次新股異動 | 泰格醫藥漲超2%創上市新高,今日將公佈中期業績
uSMART友信智投8月28日消息,次新股泰格醫藥站穩120港元上方,創上市新高,若打新中籤持有至今,不計手續費,最高一手賺2300港元。
泰格醫藥將於今天發佈中期業績。
一季報方面,泰格醫藥的招股書顯示,收入由截至2019年3月31日止三個月的6.05億元增加8.3%至截至2020年3月31日止三個月的6.55億元。同期,毛利由2.69億元增加7.3%至2.887億元。
根據彭博的一致預期,分析師預計今年上半年泰格醫藥的營業收入爲9.1億元,同比增長25%。調整後的淨利潤爲2.69億元,同比增長30.2%。
CRO同行業的康龍化成、藥明康德均已發佈中期業績:
康龍化成上半年實現收益約人民幣21.93億元(單位下同),同比增長34%;毛利約7.94億元,同比增長52.1%;母公司擁有人應佔利潤4.79億元,同比增長1.97倍;基本每股盈利0.6053元,不派息。
藥明康德上半年收益72.31億元人民幣,同比增長22.7%;毛利26.59億元,同比增長16.4%;公司擁有人應佔溢利17.17億元,同比增長62.5%;每股盈利0.75元,不派息。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.